INCY Incyte Corp - 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa’s title was changed to Executive Vice President and Head of U.S. Commercial. Dr. Cagnoni replaces William J. Meury as President, Incyte. Mr. Meury remains Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Meury, Dr. Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the “Impacted Executives”.

There were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes. Further biographical information and a description of the business experience of each of the Impacted Executives is contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on February 10, 2026, which are incorporated herein by reference.

A copy of the Company’s press release announcing the title changes is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibits

Description

99.1

Press release issued by Incyte Corporation dated March 25, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBLR document).

2